Leadership

Medicine by Design is headed by an Executive Leadership Team composed of leading experts in regenerative medicine at the University of Toronto and its affiliated hospitals.

Peter Zandstra — Executive Director

Dr. Peter Zandstra leads and provides strategic direction for Medicine by Design. He is a professor at the University of Toronto’s Institute of Biomaterials and Biomedical Engineering, with cross appointments in the departments of Chemical Engineering and Applied Chemistry and the Donnelly Centre for Cellular and Biomolecular Research. Dr. Zandstra graduated with a Bachelor of Engineering degree from McGill University in the Department of Chemical Engineering, obtained his Ph.D. from the University of British Columbia in the Department of Chemical Engineering and Biotechnology (with Jamie Piret and Connie Eaves) and continued his research training as a post-doctoral fellow in biological engineering (with Douglas Lauffenburger) at the Massachusetts Institute of Technology.

Dr. Zandstra’s research focuses on generating functional tissue from adult and pluripotent stem cells. He and his team have pioneered the field of stem cell bioengineering, which applies engineering principles to the study of stem cell biology. His work has advanced our understanding of difficult-to-access developmental processes and catalyzed creation of novel cell-based technologies that are contributing to drug discovery and cell therapy.

Dr. Zandstra is the Canada Research Chair in Stem Cell Bioengineering and has received numerous awards and fellowships, including the Premier’s Research Excellence Award (2002), the E.W.R. Steacie Memorial Fellowship (2006), the John Simon Guggenheim Memorial Foundation Fellowship (2007), the McLean Award (2009) and the Till and McCulloch Award (2013). He is a fellow of the American Institute for Medical and Biological Engineering, the American Association for the Advancement of Science and in 2015 was made a Fellow of the Royal Society of Canada (Science). In 2016, he was named University Professor, the University of Toronto’s highest academic rank.

Dr. Zandstra is chief scientific officer at CCRM and director of research and development at the Ontario Institute for Regenerative Medicine. He has directly participated in co-founding three companies, including ExCellThera, a clinical-stage company that develops technologies for robust and cost-effective blood stem cell-based therapies for leukemia and other blood diseases.


Gary Bader — Associate Director, Knowledge Mobilization

Dr. Gary D. Bader has been a member of the Donnelly Centre for Cellular and Biomolecular Research at the University of Toronto since 2006. Cross-appointed in the Department of Molecular Genetics in the Faculty of Medicine and in the Department of Computer Science, Dr. Bader works primarily in the area of biological network analysis to better understand cellular processes in normal and diseased tissues. With a background in biochemistry and computer science, Dr. Bader completed a post-doctoral fellowship at the Memorial Sloan-Kettering Cancer Center in New York after earning his PhD in biochemistry from the University of Toronto in 2002 and his undergraduate degree in 1997 at McGill University. Dr. Bader has published more than 150 peer-reviewed articles, which have garnered more than 28,000 citations.


Gordon Keller — Associate Director, Faculty Recruitment

Head shot of Gordon KellerDr. Gordon Keller earned his PhD in immunology at the University of Alberta in 1979 and completed a post-doctoral fellowship at the Ontario Cancer Institute in Toronto in 1983. Following his studies, Dr. Keller became a member of the Basel Institute for Immunology in Switzerland, where he worked for five years, before becoming a visiting scientist at the Research Institute of Molecular Pathology in Vienna, Austria.  In 1990, he moved to the United States, working initially at the National Jewish Centre for Immunology and Respiratory Medicine in Denver, Colorado, and from 1999 to 2006 as a Professor in the Department of Gene and Cell Medicine at the Mount Sinai School of Medicine in New York. In 2005, he was appointed director of the Black Family Stem Cell Institute within the Mount Sinai School of Medicine. In 2007, Dr. Keller returned to Canada to become director of the McEwen Centre for Regenerative Medicine at the University Health Network in Toronto. Dr. Keller is best known for his research in lineage-specific differentiation of mouse and human embryonic stem cells.


Shana Kelley— Associate Director, Commercialization

Dr. Shana Kelley is a Distinguished Professor of Pharmaceutical Sciences, Chemistry, Biochemistry and Biomedical Engineering at the University of Toronto. Dr. Kelley received her PhD from the California Institute of Technology and was a NIH postdoctoral fellow at the Scripps Research Institute.

The Kelley research group works in a variety of areas spanning bioanalytical chemistry, chemical biology and nanotechnology. Dr. Kelley’s work has been recognized with a variety of distinctions, including being named one of “Canada’s Top 40 under 40,” a NSERC E.W.R. Steacie Fellow, the 2011 Steacie Prize, and the 2016 NSERC Brockhouse Prize. She has also been recognized with the Pittsburgh Conference Achievement Award, an Alfred P. Sloan Research Fellowship, a Camille Dreyfus Teacher-Scholar award, a NSF CAREER Award, a Dreyfus New Faculty Award, and was also named a “Top 100 Innovator” by MIT’s Technology Review. She is a founder of two molecular diagnostics companies, GeneOhm Sciences (acquired by Becton Dickinson in 2005) and Xagenic Inc.


Andras Nagy — Associate Director, International Partnerships

Dr. Andras Nagy is a Shawn Kimel Senior Scientist at the Lunenfeld-Tanenbaum Research Institute, Sinai Health System, professor in the Department of Obstetrics & Gynaecology and Institute of Medical Science at the University of Toronto, investigator at the McEwen Centre for Regenerative Medicine and Adjunct Professor at the Monash University, Melbourne. He holds a Tier I Canada Research Chair in Stem Cells and Regeneration. He also has a Fellowship of the Royal Society of Canada in the Life Sciences Division of the Academy of Science. Dr. Nagy has made significant breakthroughs in the development of mouse and human pluripotent stem cells (both embryonic and induced) that could accelerate research in regenerative medicine and lead to future therapies for currently incurable diseases, such as blindness, diabetes, arthritis, spinal cord injury and many others. His team created the first two Canadian human embryonic stem cell lines and developed a novel method for generating non-viral induced pluripotent stem cells. His current research focuses on understanding the process of reprogramming to stem cells at the molecular level and using sophisticated genome editing methodology to pave the way for safe and effective cell-based therapies.


Thomas Waddell — Associate Director, Clinical Translation

Photo of Dr. Tom WaddellDr. Thomas Waddell is the Pearson-Ginsberg Chair in the Division of Thoracic Surgery at the University of Toronto, and head of the Division of Thoracic Surgery at University Health Network, including Toronto General Hospital. Dr. Waddell received his MD from the University of Ottawa in 1987, where he received the gold medal in surgery. He completed a surgical internship at St. Michael’s Hospital before joining the University of Toronto general surgery residency program. He pursued basic laboratory training for five years as part of the Surgical Scientist Program, completing his MSc with Alec Patterson in 1992 and his PhD with Greg Downey in 1995.

Dr. Waddell has received numerous honours for his research work, including the Governor General’s Gold Medal and the Royal College Prize for Resident Research.  He completed general surgery training in 1997 and his thoracic surgery fellowship in 1998. Following completion of clinical training, he undertook an additional year of laboratory research as a McLaughlin Fellow at Imperial College in London, England. He was appointed assistant professor in 2000, promoted to associate professor in 2004 and was promoted to full professor in 2010.  He has earned numerous distinctions, including the Blalock Scholarship from the American Association for Thoracic Surgery, a CIHR New investigator Award, a CFI New Opportunities Fund Award, the George Armstrong Peters Prize in the Department of Surgery and a Wightman-Berris Individual Teaching Award, and was recognized with the R. Fraser Elliott Chair in Transplantation Research in 2005 and the Richard and Heather Thomson Chair in Translational Research in 2010. In 2011, he received the the Lister Prize, the highest research honour from the University of Toronto Department of Surgery.

Dr. Waddell runs a large lab with funding from the Thoracic Surgery Foundation for Research and Education, CIHR, Heart and Stroke, the Canadian Cystic Fibrosis Foundation, the Roche Organ Transplantation Research Foundation, the PSI Foundation and the Ontario Institute for Cancer Research.  His laboratory focuses on alternative approaches to the chronic shortage of donor lungs, especially stem cell and regenerative medicine approaches to lung disease.  He leads the lung group for the McEwen Centre for Regenerative Medicine. His clinical interests include lung transplantation and lung volume reduction surgery, lung cancer and especially minimally invasive and robotic thoracic surgery.

Dr. Waddell has co-founded two companies related to lung re-conditioning for lung transplantion (EVLP), including XOR Labs Toronto Inc.